Skip to main content
    U

    Ultragenyx (RARE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.90
    -0.18 (-1.12%)

    Market Cap: $1.64B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Ultragenyx (RARE) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Ultragenyx are Nurix Therapeutics (NRIX), Uniqure NV (QURE) and UroGen Pharma (URGN). By market cap, Ultragenyx ranks 7th of the 13 companies on this page; Pharvaris BV (PHVS) is the largest at $2.36B. The median P/E of the 4 companies with a P/E is 27.3x.

    Peer Comparison

    RARE's revenue growth of 8.1% is below the peer median of 17.4%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Ultragenyx (RARE)$1.64BN/A2.2x-71.8%N/A8.1%0.00%
    Nurix Therapeutics Inc (NRIX)$1.69B6.4x2.3x42.0%N/A8426.0%0.00%
    Uniqure NV (QURE)$1.67BN/A75.8x0.0%-57.9%40.4%0.00%
    UroGen Pharma Ltd (URGN)$1.28BN/A5.7x-26.3%-73.7%223.9%0.00%
    Precigen Inc (PGEN)$1.63B98.6x9.9x15.5%18.9%2438.0%0.00%
    Nuvation Bio Inc (NUVB)$1.41BN/A6.7x-67.4%-18.7%242.6%0.00%
    Aurinia Pharmaceuticals Inc (AUPH)$2.11B15.2x6.4x97.7%N/A13.9%0.00%
    Pharvaris BV (PHVS)$2.36BN/AN/A0.0%N/A0.0%0.00%
    Sarepta Therapeutics Inc (SRPT)$1.72BN/A0.8x-5.9%-3.2%-4.5%0.00%
    Septerna, Inc. Common Stock (SEPN)$2.03BN/A20.3x-61.3%N/A-12.2%0.00%
    Novavax Inc (NVAX)$1.41BN/A3.2x-18.6%-66.6%-3.0%0.00%
    Pharming Group NV (PHAR)$891.80M39.3x2.4x6.3%7.9%20.8%0.00%
    Nektar Therapeutics (NKTR)$1.27BN/A23.9x0.0%N/A-20.4%0.00%
    Peer median$1.65B27.3x6.4x0.0%-18.7%17.4%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Ultragenyx, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Nurix Therapeutics Inc (NRIX)
    Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development...
    NRIX competitors
    Uniqure NV (QURE)
    uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases.
    QURE competitors
    UroGen Pharma Ltd (URGN)
    UroGen Pharma Ltd (URGN) is an innovative biotechnology company focused on the development of advanced therapies for urological diseases...
    URGN competitors
    Precigen Inc (PGEN)
    Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.
    PGEN competitors
    Nuvation Bio Inc (NUVB)
    Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology.
    NUVB competitors
    Aurinia Pharmaceuticals Inc (AUPH)
    Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China.
    AUPH competitors
    Pharvaris BV (PHVS)
    Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies.
    PHVS competitors
    Sarepta Therapeutics Inc (SRPT)
    Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy...
    SRPT competitors
    Septerna, Inc. Common Stock (SEPN)
    Septerna, Inc. is a cutting-edge biotechnology firm dedicated to transforming disease treatment through its advanced selective protein modulation platform.
    SEPN competitors
    Novavax Inc (NVAX)
    Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases...
    NVAX competitors
    Pharming Group NV (PHAR)
    Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States...
    PHAR competitors
    Nektar Therapeutics (NKTR)
    Nektar Therapeutics is a biopharmaceutical company.
    NKTR competitors

    Frequently Asked Questions About RARE

    Who are Ultragenyx's main competitors?

    The companies most similar to Ultragenyx include Nurix Therapeutics (NRIX), Uniqure NV (QURE), UroGen Pharma (URGN), Precigen (PGEN) and Nuvation Bio (NUVB), listed from the closest match.

    Who is Ultragenyx's biggest competitor?

    Pharvaris BV (PHVS) is the largest of the similar companies at $2.36B; Nurix Therapeutics (NRIX) is the closest match by business profile, size, sector and industry.

    How does RARE stock compare with its competitors?

    RARE's P/S is 2.2x against a peer median of 6.4x; its net margin is -71.8% against a peer median of 0.0%.

    Which of Ultragenyx's competitors pays a higher dividend?

    Ultragenyx pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Ultragenyx bigger than its competitors?

    No. Ultragenyx is 7th by market cap among the 13 companies on this page; the largest is Pharvaris BV (PHVS) at $2.36B.